An open label, multi-centre, prospective study to demonstrate safety and efficacy of once daily Advagraf in patients undergoing kidney or liver transplantation in India.

Trial Profile

An open label, multi-centre, prospective study to demonstrate safety and efficacy of once daily Advagraf in patients undergoing kidney or liver transplantation in India.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Tacrolimus (Primary) ; Immunosuppressants
  • Indications Liver transplant rejection; Renal transplant rejection
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 22 Aug 2012 Planned End Date 31 Jan 2013 added as reported by Clinical Trial Registry - India record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top